共 10 条
- [1] IS 25MG ETANERCEPT EFFECTIVE IN MAINTAINING A CLINICAL RESPONSE IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO HAVE RESPONDED TO 50MG ONCE WEEKLY: A MULTICENTRE RANDOMISED CONTROLLED TRIALCLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (05) : 790 - 790Elender, F.Hamilton, L.Yates, M.Dean, L.Doll, H.Thomas, H.Gaffney, K.
- [2] Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control TrialJOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1177 - 1185Yates, MaxHamilton, Louise E.Elender, FrancesDean, LorettaDoll, HelenMacGregor, Alex J.Thomas, JoegiGaffney, Karl
- [3] Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitisANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (12) : 1572 - 1577van der Heijde, D.Da Silva, J. C.Duougados, M.Geher, P.van der Horst-Bruinma, I.Juanola, X.Olivieri, I.Raeman, F.Settas, L.Sieper, J.Szechinski, J.Walker, D.Boussuge, M-PWajdula, J. S.Paolozzi, L.Fatenejad, S.
- [4] A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasisBMC DERMATOLOGY, 2016, 16Lee, Joo-HeungYoun, Jai-IlKim, Tae-YoonChoi, Jee-HoPark, Chul-JongChoe, Yong-BeomSong, Hae-JunKim, Nack-InKim, Kwang-JoongLee, Jeung-HoonYoo, Hyun-Jeong
- [5] Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extensionBRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (05) : 1177 - 1185van de Kerkhof, P. C. M.Segaert, S.Lahfa, M.Luger, T. A.Karolyi, Z.Kaszuba, A.Leigheb, G.Camacho, F. M.Forsea, D.Zang, C.Boussuge, M. P.Paolozzi, L.Wajdula, J.
- [6] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialTRIALS, 2014, 15 (01)Hill, Nathan R.Lasserson, DanielThompson, BenPerera-Salazar, RafaelWolstenholme, JaneBower, PeterBlakeman, ThomasFitzmaurice, DavidLittle, PaulFeder, GeneQureshi, NadeemTaal, MaartenTownend, JonathanFerro, CharlesMcManus, RichardHobbs, F. D. Richard
- [7] Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialTrials, 23Nathan R. HillDaniel LassersonBen ThompsonRafael Perera-SalazarJane WolstenholmePeter BowerThomas BlakemanDavid FitzmauricePaul LittleGene FederNadeem QureshiMaarten TaalJonathan TownendCharles FerroRichard McManusF. D. Richard Hobbs
- [8] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialTrials, 15 (1)Nathan R HillDaniel LassersonBen ThompsonRafael Perera-SalazarJane WolstenholmePeter BowerThomas BlakemanDavid FitzmauricePaul LittleGene FederNadeem QureshiMaarten TaalJonathan TownendCharles FerroRichard McManusFD Richard Hobbs
- [9] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialTRIALS, 2014, 15Hill, Nathan R.Lasserson, DanielThompson, BenPerera-Salazar, RafaelWolstenholme, JaneBower, PeterBlakeman, ThomasFitzmaurice, DavidLittle, PaulFeder, GeneQureshi, NadeemTaal, MaartenTownend, JonathanFerro, CharlesMcManus, RichardHobbs, F. D. Richard
- [10] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (vol 15, 160, 2014)TRIALS, 2022, 23 (01)Hill, Nathan R.Lasserson, DanielThompson, BenPerera-Salazar, RafaelWolstenholme, JaneBower, PeterBlakeman, ThomasFitzmaurice, DavidLittle, PaulFeder, GeneQureshi, NadeemTaal, MaartenTownend, JonathanFerro, CharlesMcManus, RichardHobbs, F. D. Richard